evogliptin hydrochloride

Evogliptin(DA-1229) is a potent and selective DPP4 inhibitor (dipeptidyl peptidase 4 inhibitor) that can improve insulin resistance and delays the onset of diabetes. Evogliptin delays the onset of diabetes in young db db mice and improves insulin sensitiv

Evogliptin (DA-1229) 是具有口服活性的DPP4抑制剂。Evogliptin 在小鼠模型中具有显著而持久的降糖效果。Evogliptin 通过诱导自噬抑制肝细胞的纤维化和炎症信号的产生。Evogliptin 可用于 2 型糖尿病、慢性肝脏炎症，骨质疏松症及肾功能损害的研究。

Evogliptin tartrate has potential for anti-atherosclerosis therapy that targets arterial inflammation. Evogliptin tartrate is a potent, orally bioavailable and selective dipeptidyl peptidase-4 (DPP-4) inhibitor, with antidiabetic activity.